As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of IDEAYA Biosciences, Inc. The largest reported stake is Janus Henderson Group Plc's, at 8.3%. 10 filings are on record since August 13, 2025 (Schedule 13G/A, May 15, 2026).
Sell to companies like IDEAYA Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Baker Bros. Advisors LP · Sole voting: 5,010,030 · Shared voting: 0 · Sole dispositive: 5,010,030 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Vanguard Capital Management · Sole voting: 702,125 · Shared voting: 0 · Sole dispositive: 4,834,771 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-31
- · Reporting person: Janus Henderson Group Plc · Sole voting: 0 · Shared voting: 7,265,253 · Sole dispositive: 0 · Shared dispositive: 7,265,253 · SCHEDULE 13G/A, 2026-05-15
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-27
- · Holder: Point72 Asset Management, L.P. · Percent: 2.1% · SCHEDULE 13G/A
IDEAYA Biosciences, Inc. has 10 Schedule 13D or 13G filings on record since 2025-08-13. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Janus Henderson Group Plc | 8.3% | 7,265,253 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Capital Research Global Investors | 6% | 5,279,675 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| Baker Bros. Advisors LP | 5.2% | 5,010,030 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Vanguard Capital Management | 5.08% | 4,834,771 | SCHEDULE 13G, 2026-07-31 | 2026-06-30 |
| Federated Hermes, Inc. | 3.87% | 3,395,771 | SCHEDULE 13G/A, 2026-01-08 | 2025-12-31 |
| Point72 Asset Management, L.P. | 2.1% | 1,844,556 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind IDEAYA Biosciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on IDEAYA Biosciences, Inc. and the records around it.
IDEAYA Biosciences, Inc. elsewhere on the record
Companies that share a holder
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Watch IDEAYA Biosciences, Inc.
Get an email when IDEAYA Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on IDEAYA Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on IDEAYA Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on IDEAYA Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Janus Henderson Group Plc | 0 | 7,265,253 | 0 | 7,265,253 | SCHEDULE 13G/A, 2026-05-15 |
| Baker Bros. Advisors LP | 5,010,030 | 0 | 5,010,030 | 0 | SCHEDULE 13G, 2026-08-14 |
| Baker Bros. Advisors (GP) LLC | 5,010,030 | 0 | 5,010,030 | 0 | SCHEDULE 13G, 2026-08-14 |
| Julian C. Baker | 5,010,030 | 0 | 5,010,030 | 0 | SCHEDULE 13G, 2026-08-14 |
| Felix J. Baker | 5,010,030 | 0 | 5,010,030 | 0 | SCHEDULE 13G, 2026-08-14 |
| Vanguard Capital Management | 702,125 | 0 | 4,834,771 | 0 | SCHEDULE 13G, 2026-07-31 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-27 |
The latest filing identifies IDEAYA Biosciences, Inc. by CUSIP 45166A102 and gives its principal executive office as 5000 Shoreline Court, Suite 300, South San Francisco, CA 94080 (SCHEDULE 13G, 2026-08-14).
What the percentages are based on
The information in Item 11 of each of the cover pages to this Schedule 13G is incorporated herein by reference. The percentage of beneficial ownership for each of the Reporting Persons reported herein is based on 96,375,637 shares of Common Stock outstanding as of June 30, 2026, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 4, 2026.Baker Bros. Advisors LP, SCHEDULE 13G, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Capital Research Global Investors | 7.5% | SCHEDULE 13G |
| 2025-08-14 | Janus Henderson Group Plc | 6.9% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 7.3% | SCHEDULE 13G/A |
| 2026-01-08 | Federated Hermes, Inc. | 3.87% | SCHEDULE 13G/A |
| 2026-02-12 | Capital Research Global Investors | 6% | SCHEDULE 13G/A |
| 2026-02-17 | Point72 Asset Management, L.P. | 2.1% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 8.3% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Capital Management | 5.08% | SCHEDULE 13G |
| 2026-08-14 | Baker Bros. Advisors LP | 5.2% | SCHEDULE 13G |
Questions about who owns IDEAYA Biosciences, Inc.
Who owns IDEAYA Biosciences, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of IDEAYA Biosciences, Inc.: Janus Henderson Group Plc (8.3%, Schedule 13G/A, filed 2026-05-15), Capital Research Global Investors (6%, Schedule 13G/A, filed 2026-02-12), Baker Bros. Advisors LP (5.2%, Schedule 13G, filed 2026-08-14) and Vanguard Capital Management (5.08%, Schedule 13G, filed 2026-07-31).
Who are the largest shareholders of IDEAYA Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of IDEAYA Biosciences, Inc. on this page are Janus Henderson Group Plc (8.3%), Capital Research Global Investors (6%) and Baker Bros. Advisors LP (5.2%).
When did Janus Henderson Group Plc buy into IDEAYA Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G/A, filed 2025-08-14, reporting 6.9%; its latest, Schedule 13G/A filed 2026-05-15, reports 8.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for IDEAYA Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.